Identification

Name
Lisdexamfetamine
Accession Number
DB01255
Type
Small Molecule
Groups
Approved, Investigational
Description

Lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine coupled with the essential amino acid L-lysine. It was developed so that the amphetamine psychostimulant is released and activated more slowly as the prodrug molecule is hydrolyzed consequently cleaving off the amino acid-during the first pass through the intestines and/or the liver. Amphetamines target the trace amine-associated receptor 1 (TAAR1). Amphetamine is also believed to exert its effects by binding to the monoamine transporters (the dopamine transporter or DAT) and increasing extracellular levels of the biogenic amines dopamine, norepinephrine (noradrenaline) and serotonin.

Structure
Thumb
Synonyms
  • Lisdexamfetamine
  • lisdexamfetamine dimesylate
  • NRP104
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VyvanseCapsule20 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2007-12-102018-03-22Us
VyvanseCapsule70 mg/1OralShire2007-02-23Not applicableUs
VyvanseCapsule70 mgOralShire Pharma Canada Ulc2017-01-05Not applicableCanada
VyvanseCapsule20 mg/1OralShire2007-12-10Not applicableUs
VyvanseCapsule50 mgOralShire Pharma Canada Ulc2009-08-04Not applicableCanada
VyvanseCapsule70 mg/1OralAvera Mc Kennan Hospital2015-09-302018-05-31Us
VyvanseTablet, chewable50 mg/1OralShire2017-01-28Not applicableUs
VyvanseCapsule50 mg/1OralPhysicians Total Care, Inc.2008-07-11Not applicableUs
VyvanseTablet, chewable20 mg/1OralShire2017-01-28Not applicableUs
VyvanseCapsule40 mg/1OralShire2007-12-10Not applicableUs
Categories
UNII
H645GUL8KJ
CAS number
608137-32-2
Weight
Average: 263.3785
Monoisotopic: 263.199762437
Chemical Formula
C15H25N3O
InChI Key
VOBHXZCDAVEXEY-JSGCOSHPSA-N
InChI
InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
IUPAC Name
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
SMILES
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN

Pharmacology

Indication

For the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric populations aged 6 to 12 years.

Associated Conditions
Pharmacodynamics

Lisdexamfetamine is a pro-drug of dextroamphetamine. It works primarily by inducing the release of the neurotransmitters dopamine and norepinephrine from their storage areas in nerve terminals. Both of these transmitters contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation.

Mechanism of action

Lisdexamfetamine is a pro-drug of dextroamphetamine. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Norepinephrine and dopamine contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation. However, the exact therapeutic action in ADHD is not known.

TargetActionsOrganism
ASodium-dependent dopamine transporter
inhibitor
Human
UAlpha-1B adrenergic receptor
antagonist
Human
Absorption

After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Lisdexamfetamine is converted to dextroamphetamine and L-lysine, which is believed to occur by first-pass intestinal and/or hepatic metabolism. Lisdexamfetamine is not metabolized by cytochrome P450 enzymes.

Route of elimination
Not Available
Half life

The plasma elimination half-life of lisdexamfetamine typically averaged less than one hour.

Clearance
Not Available
Toxicity

Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineLisdexamfetamine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Lisdexamfetamine.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Lisdexamfetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Lisdexamfetamine.Approved
AcrivastineLisdexamfetamine may decrease the sedative activities of Acrivastine.Approved
AdrafinilLisdexamfetamine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineLisdexamfetamine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AlcaftadineLisdexamfetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilLisdexamfetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
AlimemazineLisdexamfetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
AlphacetylmethadolLisdexamfetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineLisdexamfetamine may increase the analgesic activities of Alphaprodine.Illicit
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Withdrawn
AluminiumAluminium may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
AmibegronLisdexamfetamine may decrease the vasoconstricting activities of Amibegron.Investigational
AmineptineAmineptine may increase the stimulatory activities of Lisdexamfetamine.Illicit, Withdrawn
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
AmitrazLisdexamfetamine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Lisdexamfetamine.Approved
AmitriptylinoxideAmitriptylinoxide may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
AmlodipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Amlodipine.Approved
Ammonium chlorideThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmoxapineAmoxapine may increase the antihypertensive activities of Lisdexamfetamine.Approved
AmperozideAmperozide may decrease the stimulatory activities of Lisdexamfetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Amrinone.Approved
AnisodamineLisdexamfetamine may decrease the vasoconstricting activities of Anisodamine.Investigational
AntazolineLisdexamfetamine may decrease the sedative activities of Antazoline.Approved
ApomorphineLisdexamfetamine may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineLisdexamfetamine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Aranidipine.Approved, Investigational
ArbutamineLisdexamfetamine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolLisdexamfetamine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Investigational
Ascorbic acidThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
AsenapineAsenapine may increase the antihypertensive activities of Lisdexamfetamine.Approved
AstemizoleLisdexamfetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtenololAtenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
AvanafilAvanafil may increase the hypotensive activities of Lisdexamfetamine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Lisdexamfetamine.Investigational, Vet Approved
AzatadineLisdexamfetamine may decrease the sedative activities of Azatadine.Approved
AzelastineLisdexamfetamine may decrease the sedative activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Azimilide.Investigational
BambuterolLisdexamfetamine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BamipineLisdexamfetamine may decrease the sedative activities of Bamipine.Experimental
BarnidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Benidipine.Approved, Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Benmoxin.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
BenzatropineLisdexamfetamine may decrease the sedative activities of Benzatropine.Approved
BenzphetamineLisdexamfetamine may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BenzquinamideLisdexamfetamine may decrease the sedative activities of Benzquinamide.Withdrawn
BepotastineLisdexamfetamine may decrease the sedative activities of Bepotastine.Approved
BepridilThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bepridil.Approved, Withdrawn
BetahistineLisdexamfetamine may decrease the sedative activities of Betahistine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Lisdexamfetamine.Approved
BezitramideLisdexamfetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Lisdexamfetamine.Investigational
BilastineLisdexamfetamine may decrease the sedative activities of Bilastine.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bioallethrin.Approved, Experimental
Bismuth subcitrate potassiumBismuth Subcitrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
BitolterolLisdexamfetamine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
BrexpiprazoleLisdexamfetamine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineLisdexamfetamine may decrease the vasoconstricting activities of Brimonidine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Brofaromine.Experimental
BromocriptineLisdexamfetamine may decrease the vasoconstricting activities of Bromocriptine.Approved, Investigational
BromodiphenhydramineLisdexamfetamine may decrease the sedative activities of Bromodiphenhydramine.Approved
BromperidolBromperidol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
BrompheniramineLisdexamfetamine may decrease the sedative activities of Brompheniramine.Approved
BucindololBucindolol may increase the antihypertensive activities of Lisdexamfetamine.Investigational
BuclizineLisdexamfetamine may decrease the sedative activities of Buclizine.Approved
BufuralolBufuralol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Lisdexamfetamine.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
BuprenorphineLisdexamfetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Lisdexamfetamine.Experimental
ButorphanolLisdexamfetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved
Butyric AcidLisdexamfetamine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Experimental
CarbinoxamineLisdexamfetamine may decrease the sedative activities of Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Carboxyamidotriazole.Investigational
CarfentanilLisdexamfetamine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
CaroverineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Caroverine.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Caroxazone.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
CetirizineLisdexamfetamine may decrease the sedative activities of Cetirizine.Approved
ChlorcyclizineLisdexamfetamine may decrease the sedative activities of Chlorcyclizine.Approved
ChloropyramineLisdexamfetamine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineLisdexamfetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineLisdexamfetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Lisdexamfetamine.Experimental
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational, Withdrawn
CilnidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Cilnidipine.Approved, Investigational
CimetidineLisdexamfetamine may decrease the sedative activities of Cimetidine.Approved, Investigational
CinnarizineLisdexamfetamine may decrease the sedative activities of Cinnarizine.Approved, Investigational
CirazolineLisdexamfetamine may decrease the vasoconstricting activities of Cirazoline.Experimental
ClemastineLisdexamfetamine may decrease the sedative activities of Clemastine.Approved, Investigational
ClenbuterolLisdexamfetamine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Clevidipine.Approved, Investigational
ClofedanolLisdexamfetamine may decrease the sedative activities of Clofedanol.Approved, Withdrawn
ClomipramineClomipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational, Vet Approved
ClonidineLisdexamfetamine may decrease the vasoconstricting activities of Clonidine.Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Lisdexamfetamine.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Lisdexamfetamine.Experimental
ClozapineClozapine may increase the antihypertensive activities of Lisdexamfetamine.Approved
CodeineLisdexamfetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Lisdexamfetamine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Cyclandelate.Approved
CyclizineLisdexamfetamine may decrease the sedative activities of Cyclizine.Approved
CyproheptadineLisdexamfetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Lisdexamfetamine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lisdexamfetamine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Darodipine.Experimental
DesipramineDesipramine may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
DesloratadineLisdexamfetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DetomidineLisdexamfetamine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexbrompheniramineLisdexamfetamine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineLisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateLisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DexmedetomidineLisdexamfetamine may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Illicit
DextromoramideLisdexamfetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneLisdexamfetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineLisdexamfetamine may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of Lisdexamfetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
DihydrocodeineLisdexamfetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineLisdexamfetamine may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DihydroetorphineLisdexamfetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineLisdexamfetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Diltiazem.Approved, Investigational
DimenhydrinateLisdexamfetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetacrineDimetacrine may increase the stimulatory activities of Lisdexamfetamine.Approved, Withdrawn
DimetindeneLisdexamfetamine may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazineLisdexamfetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineLisdexamfetamine may decrease the sedative activities of Diphenhydramine.Approved, Investigational
DiphenoxylateLisdexamfetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DiphenylpyralineLisdexamfetamine may decrease the sedative activities of Diphenylpyraline.Approved, Investigational
DipivefrinLisdexamfetamine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Lisdexamfetamine.Approved
DixyrazineDixyrazine may decrease the stimulatory activities of Lisdexamfetamine.Experimental
DL-MethylephedrineLisdexamfetamine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineLisdexamfetamine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineLisdexamfetamine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DosulepinDosulepin may increase the stimulatory activities of Lisdexamfetamine.Approved
DotarizineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Lisdexamfetamine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
DoxofyllineLisdexamfetamine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxylamineLisdexamfetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPELisdexamfetamine may increase the analgesic activities of DPDPE.Experimental
DronedaroneDronedarone may increase the antihypertensive activities of Lisdexamfetamine.Approved
DroperidolDroperidol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Vet Approved
DroxidopaLisdexamfetamine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EbastineLisdexamfetamine may decrease the sedative activities of Ebastine.Approved, Investigational
EcopipamEcopipam may decrease the stimulatory activities of Lisdexamfetamine.Investigational
EfonidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Efonidipine.Approved, Investigational
EmedastineLisdexamfetamine may decrease the sedative activities of Emedastine.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Eperisone.Approved, Investigational
EphedraLisdexamfetamine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineLisdexamfetamine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineLisdexamfetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineLisdexamfetamine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovineLisdexamfetamine may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotamineLisdexamfetamine may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
EsmirtazapineLisdexamfetamine may decrease the sedative activities of Esmirtazapine.Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
EtafedrineLisdexamfetamine may decrease the vasoconstricting activities of Etafedrine.Approved
EthopropazineLisdexamfetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideLisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Withdrawn
EthylmorphineLisdexamfetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineLisdexamfetamine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateLisdexamfetamine may decrease the vasoconstricting activities of Etomidate.Approved
EtoperidoneLisdexamfetamine may decrease the sedative activities of Etoperidone.Withdrawn
EtorphineLisdexamfetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineLisdexamfetamine may decrease the sedative activities of Famotidine.Approved
FelodipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Fendiline.Withdrawn
FenoterolLisdexamfetamine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylLisdexamfetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineLisdexamfetamine may decrease the sedative activities of Fexofenadine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Fish oil.Approved, Nutraceutical
FluanisoneFluanisone may decrease the stimulatory activities of Lisdexamfetamine.Experimental
FlunarizineLisdexamfetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
FormoterolLisdexamfetamine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Lisdexamfetamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Gallopamil.Investigational
Glutamic AcidThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanabenzLisdexamfetamine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanethidineThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Guanethidine.Approved
GuanfacineLisdexamfetamine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HaloperidolHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Harmaline.Experimental
HeroinLisdexamfetamine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HexoprenalineLisdexamfetamine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineLisdexamfetamine may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Hydracarbazine.Experimental
HydrocodoneLisdexamfetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneLisdexamfetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Experimental, Investigational
HydroxyzineLisdexamfetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may increase the antihypertensive activities of Lisdexamfetamine.Approved
ImipramineImipramine may increase the antihypertensive activities of Lisdexamfetamine.Approved
IndacaterolLisdexamfetamine may decrease the vasoconstricting activities of Indacaterol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Lisdexamfetamine.Withdrawn
Ioflupane I-123Lisdexamfetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Lisdexamfetamine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Lisdexamfetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Lisdexamfetamine.Approved
IsoetarineLisdexamfetamine may decrease the vasoconstricting activities of Isoetarine.Approved
IsomethepteneLisdexamfetamine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineLisdexamfetamine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsothipendylLisdexamfetamine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineLisdexamfetamine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Isradipine.Approved, Investigational
KetobemidoneLisdexamfetamine may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenLisdexamfetamine may decrease the sedative activities of Ketotifen.Approved
LabetalolLabetalol may increase the antihypertensive activities of Lisdexamfetamine.Approved
LacidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lacidipine.Approved, Investigational
LafutidineLisdexamfetamine may decrease the sedative activities of Lafutidine.Investigational
LamotrigineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Investigational
LavoltidineLisdexamfetamine may decrease the sedative activities of Lavoltidine.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LevocabastineLisdexamfetamine may decrease the sedative activities of Levocabastine.Approved, Investigational
LevocetirizineLisdexamfetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateLisdexamfetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolLisdexamfetamine may increase the analgesic activities of Levorphanol.Approved
LevosalbutamolLisdexamfetamine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lidoflazine.Experimental
Lithium cationLithium may decrease the stimulatory activities of Lisdexamfetamine.Experimental
LodoxamideLisdexamfetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilLisdexamfetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Lisdexamfetamine.Experimental
LofexidineLisdexamfetamine may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Loperamide.Approved
LoratadineLisdexamfetamine may decrease the sedative activities of Loratadine.Approved, Investigational
LorpiprazoleLisdexamfetamine may decrease the sedative activities of Lorpiprazole.Approved
LoxapineLoxapine may decrease the stimulatory activities of Lisdexamfetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
MagaldrateMagaldrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
Magnesium oxideMagnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
ManidipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Manidipine.Approved, Investigational
MaprotilineLisdexamfetamine may decrease the sedative activities of Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Mebanazine.Withdrawn
MeclizineLisdexamfetamine may decrease the sedative activities of Meclizine.Approved
MedetomidineLisdexamfetamine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MelitracenMelitracen may increase the stimulatory activities of Lisdexamfetamine.Experimental, Investigational
MelperoneMelperone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Menthol.Approved
MephentermineLisdexamfetamine may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
MeptazinolLisdexamfetamine may increase the analgesic activities of Meptazinol.Experimental
MepyramineLisdexamfetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineLisdexamfetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
MetaraminolLisdexamfetamine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneLisdexamfetamine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateLisdexamfetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineLisdexamfetamine may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethanthelineLisdexamfetamine may decrease the sedative activities of Methantheline.Approved, Investigational
MethapyrileneLisdexamfetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
MethdilazineLisdexamfetamine may decrease the sedative activities of Methdilazine.Approved
MethenamineThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
MethoxamineLisdexamfetamine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineLisdexamfetamine may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Methsuximide.Approved
MethyldopaLisdexamfetamine may decrease the vasoconstricting activities of Methyldopa.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Methylene blue.Approved, Investigational
MetiamideLisdexamfetamine may decrease the sedative activities of Metiamide.Experimental
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
MianserinLisdexamfetamine may decrease the sedative activities of Mianserin.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Mibefradil.Investigational, Withdrawn
MidodrineLisdexamfetamine may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypertensive activities of Lisdexamfetamine.Approved
MirabegronLisdexamfetamine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Lisdexamfetamine.Investigational
MirtazapineLisdexamfetamine may decrease the sedative activities of Mirtazapine.Approved
MizolastineLisdexamfetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
MolindoneMolindone may decrease the stimulatory activities of Lisdexamfetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of Lisdexamfetamine.Experimental
MorphineLisdexamfetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Lisdexamfetamine.Experimental
MoxonidineLisdexamfetamine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Naftopidil.Investigational
NalbuphineLisdexamfetamine may increase the analgesic activities of Nalbuphine.Approved
NaphazolineLisdexamfetamine may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Lisdexamfetamine.Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
NicomorphineLisdexamfetamine may increase the analgesic activities of Nicomorphine.Experimental
NifedipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nifedipine.Approved
NiguldipineNiguldipine may increase the antihypertensive activities of Lisdexamfetamine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nitrendipine.Approved, Investigational
NizatidineLisdexamfetamine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineLisdexamfetamine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineLisdexamfetamine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NormethadoneLisdexamfetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Lisdexamfetamine.Approved
NylidrinLisdexamfetamine may decrease the vasoconstricting activities of Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Octamoxin.Withdrawn
OctopamineLisdexamfetamine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
OlodaterolLisdexamfetamine may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineLisdexamfetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Lisdexamfetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of Lisdexamfetamine.Investigational
OpiumLisdexamfetamine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineLisdexamfetamine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineLisdexamfetamine may decrease the sedative activities of Orphenadrine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Lisdexamfetamine.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Otilonium.Experimental, Investigational
OxatomideLisdexamfetamine may decrease the sedative activities of Oxatomide.Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
OxycodoneLisdexamfetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxyfedrineLisdexamfetamine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineLisdexamfetamine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneLisdexamfetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Lisdexamfetamine.Experimental
OzagrelLisdexamfetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may increase the antihypertensive activities of Lisdexamfetamine.Approved
PargylinePargyline may increase the hypertensive activities of Lisdexamfetamine.Approved
PemirolastLisdexamfetamine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Lisdexamfetamine.Experimental
PentazocineLisdexamfetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lisdexamfetamine.Approved, Investigational
PerazinePerazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
PergolideLisdexamfetamine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironePerospirone may decrease the stimulatory activities of Lisdexamfetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Lisdexamfetamine.Approved
PethidineLisdexamfetamine may increase the analgesic activities of Pethidine.Approved
PhenazocineLisdexamfetamine may increase the analgesic activities of Phenazocine.Experimental
PhendimetrazineLisdexamfetamine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Lisdexamfetamine.Approved
PhenindamineLisdexamfetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Pheniprazine.Withdrawn
PheniramineLisdexamfetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine.Approved, Investigational
PhenoperidineLisdexamfetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Lisdexamfetamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Phenoxypropazine.Withdrawn
PhentolaminePhentolamine may increase the antihypertensive activities of Lisdexamfetamine.Approved
PhenylephrineLisdexamfetamine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineLisdexamfetamine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Lisdexamfetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Lisdexamfetamine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
PipamperonePipamperone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
PirbuterolLisdexamfetamine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiritramideLisdexamfetamine may increase the analgesic activities of Piritramide.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Lisdexamfetamine.Approved
PitolisantLisdexamfetamine may decrease the sedative activities of Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Pivhydrazine.Withdrawn
PizotifenPizotifen may increase the antihypertensive activities of Lisdexamfetamine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
PrazosinPrazosin may increase the antihypertensive activities of Lisdexamfetamine.Approved
PrenalterolLisdexamfetamine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Prenylamine.Withdrawn
ProcaineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Procarbazine.Approved, Investigational
ProcaterolLisdexamfetamine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Vet Approved
PromazinePromazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Vet Approved
PromethazineLisdexamfetamine may decrease the sedative activities of Promethazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
PropericiazinePropericiazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Lisdexamfetamine.Approved
PropiverinePropiverine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Lisdexamfetamine.Investigational
ProtokylolLisdexamfetamine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved
PseudoephedrineLisdexamfetamine may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineQuetiapine may increase the antihypertensive activities of Lisdexamfetamine.Approved
QuifenadineLisdexamfetamine may decrease the sedative activities of Quifenadine.Experimental
QuinidineQuinidine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
RacepinephrineLisdexamfetamine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Lisdexamfetamine.Investigational
RactopamineLisdexamfetamine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RanitidineLisdexamfetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Lisdexamfetamine.Approved
RemifentanilLisdexamfetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Withdrawn
ReproterolLisdexamfetamine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineReserpine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
RilmenidineLisdexamfetamine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolLisdexamfetamine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Lisdexamfetamine.Investigational
RitobegronLisdexamfetamine may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineLisdexamfetamine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RomifidineLisdexamfetamine may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleLisdexamfetamine may decrease the vasoconstricting activities of Ropinirole.Approved, Investigational
Roxatidine acetateLisdexamfetamine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
RupatadineLisdexamfetamine may decrease the sedative activities of Rupatadine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Safrazine.Withdrawn
SalbutamolLisdexamfetamine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolLisdexamfetamine may decrease the vasoconstricting activities of Salmeterol.Approved
SelegilineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Seletracetam.Investigational
SertindoleSertindole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational, Withdrawn
SildenafilSildenafil may increase the hypotensive activities of Lisdexamfetamine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Lisdexamfetamine.Approved
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
SolabegronLisdexamfetamine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
SufentanilLisdexamfetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Lisdexamfetamine.Experimental
SynephrineLisdexamfetamine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Lisdexamfetamine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
TapentadolLisdexamfetamine may increase the analgesic activities of Tapentadol.Approved
TerazosinTerazosin may increase the antihypertensive activities of Lisdexamfetamine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
TerfenadineLisdexamfetamine may decrease the sedative activities of Terfenadine.Approved, Withdrawn
TerodilineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Experimental
TesmilifeneLisdexamfetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Lisdexamfetamine.Investigational
TetryzolineLisdexamfetamine may decrease the vasoconstricting activities of Tetryzoline.Approved
TheophyllineTheophylline may increase the hypotensive activities of Lisdexamfetamine.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Lisdexamfetamine.Experimental
ThioproperazineThioproperazine may increase the antihypertensive activities of Lisdexamfetamine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Lisdexamfetamine.Approved
ThonzylamineLisdexamfetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
TilidineLisdexamfetamine may increase the analgesic activities of Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved
TizanidineLisdexamfetamine may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Lisdexamfetamine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Lisdexamfetamine.Approved
TramadolLisdexamfetamine may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastLisdexamfetamine may decrease the sedative activities of Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
TretoquinolLisdexamfetamine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
TrifluperidolTrifluperidol may decrease the stimulatory activities of Lisdexamfetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Lisdexamfetamine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Trimethadione.Approved
TrimipramineTrimipramine may increase the antihypertensive activities of Lisdexamfetamine.Approved
TripelennamineLisdexamfetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineLisdexamfetamine may decrease the sedative activities of Triprolidine.Approved
TritoqualineLisdexamfetamine may decrease the sedative activities of Tritoqualine.Approved
TromethamineTromethamine may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved
TulobuterolLisdexamfetamine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Lisdexamfetamine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Lisdexamfetamine.Investigational
VardenafilVardenafil may increase the hypotensive activities of Lisdexamfetamine.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Lisdexamfetamine.Experimental
VerapamilVerapamil may increase the antihypertensive activities of Lisdexamfetamine.Approved
VilanterolLisdexamfetamine may decrease the vasoconstricting activities of Vilanterol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with WIN 55212-2.Experimental
XamoterolLisdexamfetamine may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineLisdexamfetamine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineLisdexamfetamine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the antihypertensive activities of Lisdexamfetamine.Approved
ZonisamideThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Zonisamide.Approved, Investigational
ZotepineZotepine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Michael J. Bauer, Gary Richard Callen, Judi Christine Humphrey, Todd Jeffrey Johnson, Matthew Wendell Schiesher, "Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof." U.S. Patent US20120157706, issued June 21, 2012.

US20120157706
General References
  1. Jasinski DR, Krishnan S: Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009 Jun;23(4):410-8. doi: 10.1177/0269881108093841. Epub 2008 Jul 17. [PubMed:18635707]
  2. Madaan V: Lisdexamfetamine dimesylate for childhood ADHD. Drugs Today (Barc). 2008 May;44(5):319-24. doi: 10.1358/dot.2008.44.5.1215724. [PubMed:18548134]
  3. Krishnan S, Moncrief S: An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):180-4. Epub 2006 Oct 11. [PubMed:17035599]
External Links
Human Metabolome Database
HMDB0015385
PubChem Compound
11597698
PubChem Substance
46505358
ChemSpider
9772458
ChEBI
135925
ChEMBL
CHEMBL1201222
Therapeutic Targets Database
DAP000571
PharmGKB
PA164748975
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lisdexamfetamine
ATC Codes
N06BA12 — Lisdexamfetamine
AHFS Codes
  • 28:20.04 — Amphetamines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMethamphetamine Dependence1
1CompletedNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentDrug Users / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1TerminatedNot AvailableHealthy Volunteers1
1, 2CompletedBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)1
1, 2CompletedTreatmentAmphetamine-Related Disorders / Attention Deficit Disorder With Hyperactivity / Substance-Related Disorders1
1, 2CompletedTreatmentDependence, Cocaine2
2Active Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Deficient Emotional Self-Regulation (DESR)1
2CompletedNot AvailableSleep Deprivation1
2CompletedTreatmentAmphetamine-Related Disorders / Attention Deficit Disorder With Hyperactivity / Substance-Related Disorders1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentBinge Eating Disorder (BED)1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentMajor Depressive Disorder (MDD)3
2CompletedTreatmentSchizophrenia and Predominant Negative Symptoms1
2CompletedTreatmentSevere Mood Dysregulation1
2RecruitingNot AvailableBinge Eating Disorder (BED)1
2RecruitingTreatmentAttention Deficit Disorder (ADD) / Attention Deficit Disorder With Hyperactivity (ADHD)1
2RecruitingTreatmentBulimia Nervosa (BN)1
3CompletedNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
3CompletedTreatmentAttention Deficit Disorder (ADD) / Traumatic Brain Injury (TBI)1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)7
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Attention Deficit Disorders With Hyperactivity1
3CompletedTreatmentAttention-Deficit/Hyperactivity Disorder1
3CompletedTreatmentBinge Eating Disorder (BED)5
3CompletedTreatmentMajor Depressive Disorder (MDD)2
3RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
3RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Attention-Deficit/Hyperactivity Disorder1
3TerminatedTreatmentBipolar / Depression1
3TerminatedTreatmentDepression, Bipolar1
3TerminatedTreatmentMajor Depressive Disorder (MDD)1
4CompletedNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)2
4CompletedBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)2
4CompletedBasic ScienceAttention Deficit/Hyperactivity Disorder1
4CompletedTreatmentADHD Specifically With Executive Function Impairment1
4CompletedTreatmentAdult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)6
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Deficient Emotional Self-Regulation (DESR)1
4CompletedTreatmentAttention-Deficit/Hyperactivity Disorder4
4CompletedTreatmentBrain Activity / Cognition / Menopause1
4CompletedTreatmentCognitive Impairments / Myalgic Encephalomyelitis (ME)1
4CompletedTreatmentCognitive Impairments / Symptomatic Menopause1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4Not Yet RecruitingOtherLisdexamfetamine1
4Not Yet RecruitingTreatmentAttention Deficit Disorder With Hyperactivity1
4Not Yet RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Autism Spectrum Conditions/Disorders1
4RecruitingTreatmentAttention Deficit Disorder (ADD) / Traumatic Brain Injury (TBI)1
4RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)2
4RecruitingTreatmentCognitive Impairments / RRSO1
4TerminatedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / BMI >30 kg/m2 / Glucose tolerance impaired1
4TerminatedTreatmentDepression, Bipolar1
Not AvailableActive Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableCompletedNot AvailableAttention Deficit/Hyperactivity Disorder / Bipolar Disorder (BD)1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Nicotine Dependence1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Sleep1
Not AvailableNot Yet RecruitingNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD) / Problem Behavior1
Not AvailableNot Yet RecruitingBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)4
Not AvailableWithdrawnPreventionPlanned RRSO1
Not AvailableWithdrawnTreatmentCognitive Impairments / RRSO1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • New River Pharmaceuticals Inc.
  • Patheon Inc.
  • Physicians Total Care Inc.
  • Quality Care
  • Shire Inc.
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral10 mg
CapsuleOral20 mg/1
CapsuleOral20 mg
CapsuleOral30 mg
CapsuleOral30 mg/1
CapsuleOral40 mg
CapsuleOral40 mg/1
CapsuleOral50 mg
CapsuleOral50 mg/1
CapsuleOral60 mg
CapsuleOral60 mg/1
CapsuleOral70 mg/1
CapsuleOral70 mg
Tablet, chewableOral10 mg/1
Tablet, chewableOral20 mg/1
Tablet, chewableOral30 mg/1
Tablet, chewableOral40 mg/1
Tablet, chewableOral50 mg/1
Tablet, chewableOral60 mg/1
Prices
Unit descriptionCostUnit
Vyvanse 30 mg capsule6.24USD capsule
Vyvanse 50 mg capsule6.02USD capsule
Vyvanse 70 mg capsule5.85USD capsule
Vyvanse 40 mg capsule5.8USD capsule
Vyvanse 20 mg capsule5.26USD capsule
Vyvanse 60 mg capsule5.02USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7659253No2003-02-242023-02-24Us
US7718619No2003-02-242023-02-24Us
US7659254No2003-02-242023-02-24Us
US7671030No2003-02-242023-02-24Us
US7662788No2003-02-242023-02-24Us
US7687467No2003-02-242023-02-24Us
US7678770No2003-02-242023-02-24Us
US7671031No2003-02-242023-02-24Us
US7713936No2003-02-242023-02-24Us
US7674774No2003-02-242023-02-24Us
US7678771No2003-02-242023-02-24Us
US7655630No2003-02-242023-02-24Us
US7687466No2003-02-242023-02-24Us
US7223735No2003-02-242023-02-24Us
US7700561No2003-02-242023-02-24Us
US7662787No2003-02-242023-02-24Us
US7723305No2003-02-242023-02-24Us
US7105486No2003-02-242023-02-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility792 mg/mL (dimesylate salt)Not Available
logP1.06Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0877 mg/mLALOGPS
logP1.01ALOGPS
logP1.14ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.89ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area81.14 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity78.31 m3·mol-1ChemAxon
Polarizability31.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9858
Blood Brain Barrier+0.9444
Caco-2 permeable+0.664
P-glycoprotein substrateSubstrate0.6919
P-glycoprotein inhibitor INon-inhibitor0.9264
P-glycoprotein inhibitor IINon-inhibitor0.9802
Renal organic cation transporterNon-inhibitor0.8398
CYP450 2C9 substrateNon-substrate0.8303
CYP450 2D6 substrateNon-substrate0.621
CYP450 3A4 substrateNon-substrate0.7228
CYP450 1A2 substrateNon-inhibitor0.7025
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorNon-inhibitor0.7568
CYP450 3A4 inhibitorNon-inhibitor0.5499
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8494
Ames testNon AMES toxic0.7156
CarcinogenicityNon-carcinogens0.854
BiodegradationNot ready biodegradable0.8575
Rat acute toxicity2.0058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9688
hERG inhibition (predictor II)Non-inhibitor0.9004
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid amides
Alternative Parents
Amphetamines and derivatives / Phenylpropanes / N-acyl amines / Secondary carboxylic acid amides / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alpha-amino acid amide / Amphetamine or derivatives / Phenylpropane / Monocyclic benzene moiety / Fatty amide / Fatty acyl / Benzenoid / N-acyl-amine / Carboxamide group / Secondary carboxylic acid amide
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Hamidovic A, Dlugos A, Palmer AA, de Wit H: Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet. 2010 Mar;40(2):255-61. doi: 10.1007/s10519-009-9331-7. Epub 2010 Jan 21. [PubMed:20091113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on May 14, 2007 19:24 / Updated on July 16, 2018 21:21